Business
Message from the CEO to MediciNova Shareholders
Strengthening MN-001’s Scientific Foundation and Clinical OutlookLA JOLLA, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dear Fellow Shareholders, Following the recent publication in the Journal of Atherosclerosis and Thrombosis, I would like to provide additional perspective on why this research represents a significant milestone for MediciNova and our MN-001 program. The study, conducted in collaboration with a leading Japanese academic research team, revealed a novel mechanism by MN-002, the prim
About this update from Medicinova, Inc.
[{"type":"image","alt":"MediciNova, Inc.","displaySize":"","headline":null,"caption":"MediciNova, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":106,"url":"https://media.zenfs.com/en/globenewswire.com/62db50f8b37ac476fe5ebe5e889fbeee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6DQPwj.XDP.I_St06Ug3kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/62db50f8b37ac476fe5ebe5e889fbeee","width":300,"height":106}},"lazy":false},{"type":"text","content":"Strengthening MN-001’s Scientific Foundation and Clinical Outlook","length":65,"tagName":"p"},{"type":"text","content":"LA JOLLA, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) --","length":51,"tagName":"p"},{"type":"text","content":"Dear Fellow Shareholders,","length":25,"tagName":"p"},{"type":"text","content":"Following the recent publication in the Journal of Atherosclerosis and Thrombosis, I would like to provide additional perspective on why this research represents a significant milestone for MediciNova and our MN-001 program. The study, conducted in collaboration with a leading Japanese academic research team, revealed a novel mechanism by MN-002, the primary metabolite of MN-001, enhances cholesterol efflux in macrophages through upregulation of ABCA1 and ABCG1 transporters. This mechanism is critical because cholesterol efflux is the first step in Reverse Cholesterol Transport (RCT)—the body’s natural process for clearing cholesterol from arterial walls, a key driver of atherosclerosis and cardiovascular disease.","length":723,"tagName":"p"},{"type":"text","content":"Why This Matters for Our StrategyThis mechanistic insight provides strong scientific validation for the lipid profile improvements observed in prior MN-001 clinical studies. It also reinforces MN-001’s potential to address multiple interconnected metabolic disorders—hypertriglyceridemia, non-alcoholic fatty liver disease (NAFLD), and type 2 diabetes (T2DM)—conditions that share underlying pathologies of lipid dysregulation and chronic inflammation. MN-001’s multi-modal activity, including anti-inflammatory and anti-fibrotic properties, positions it uniquely among emerging therapies.","length":590,"tagName":"p"},{"type":"text","content":"Clinical Progress and Next StepsWe have completed patient enrollment in our Phase 2 trial (MN-001-NATG-202) in patie...